Aging Frailty
0
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
LongeveronMIAMI, FL
2 programsLongeveron Mesenchymal Stem CellsPHASE_1_21 trial
Longeveron Mesenchymal Stem CellsPHASE_21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
LongeveronLongeveron Mesenchymal Stem Cells
LongeveronLongeveron Mesenchymal Stem Cells
Clinical Trials (2)
Total enrollment: 212 patients across 2 trials
Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty
Start: Jul 2017Est. completion: Sep 2021150 patients
Phase 2Completed
Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty
Start: Nov 2016Est. completion: Sep 202262 patients
Phase 1/2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.